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Abstract
Background and Objective The oral direct factor Xa
inhibitor edoxaban is a P-glycoprotein (P-gp) substrate
metabolized via carboxylesterase-1 and cytochrome P450
(CYP) 3A4/5. The effect of rifampin-induced induction of
P-gp and CYP3A4/5 on transport and metabolism of
edoxaban through the CYP3A4/5 pathway was investigated
in a single-dose edoxaban study.
Methods This was a phase 1, open-label, two-treatment,
two-period, single-sequence drug interaction study in heal-
thy adults. All subjects received a single oral 60 mg edoxa-
ban dose in period 1, and 7 days of 600 mg rifampin
(2 9 300 mg capsules once daily) with a single oral edox-
aban 60 mg dose administered concomitantly on day 7 in
period 2. A 6-day washout period separated the treatments.
Plasma concentrations of edoxaban and its metabolites M4
and M6 were measured, and limited assessments of phar-
macodynamic markers of coagulation were performed.
Results In total, 34 healthy subjects were enrolled; 32
completed the study. Coadministration of rifampin with
edoxaban decreased edoxaban exposure but increased active
metabolite exposure. Rifampin increased apparent oral
clearance of edoxaban by 33 % and decreased its half-life by
50 %. Anticoagulant effects based on the prothrombin time
(PT) and the activated partial thromboplastin time (aPTT)
with and without rifampin at early time points were main-
tained to a greater-than-expected degree than with edoxaban
exposure alone, presumably because of an increased con-
tribution from the active metabolites. Edoxaban was well
tolerated in this healthy adult population.
Conclusions Rifampin reduced exposure to edoxaban
while increasing exposure to its active metabolites M4 and
M6. PT and aPTT at early time points did not change
appreciably; however, the data should be interpreted with
caution.
Key Points
Rifampin induces cytochrome P450 (CYP) 3A4/5
and P-glycoprotein. It also inhibits organic anion–
transporting polypeptide (OATP) 1B1. Edoxaban is
metabolized (\ 10 %) by CYP3A4/5 and is a
substrate for P-glycoprotein. Edoxaban’s metabolite,
M4, is a substrate for OAT1B1.
Coadministration of edoxaban with rifampin reduces
total exposure to edoxaban and simultaneously
increases exposure to its active metabolites formed
via CYP3A4/5.
Rifampin also increases exposure to the M4
metabolite, which is not formed through the
CYP3A4/5 pathway.
Edoxaban was well tolerated in healthy adults.
1 Introduction
Edoxaban is an oral direct factor Xa inhibitor [1], which is
approved in Japan and the USA [2, 3] and is under consid-
eration for approval in the European Union. Oral
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administration of edoxaban results in peak plasma concen-
trations within 1–2 h [4]. Edoxaban undergoes limited
metabolism through phase 1 and phase 2 enzymes. Phase 1
metabolism is predominantly mediated by carboxylesterase-
1 (CES-1), with a lesser contribution of cytochrome P450
(CYP) 3A4/5 [5]. CES-1 mediates formation of human-
specific metabolite M4, while CYP3A4/5 mediates forma-
tion of M6 [5]. Both are active metabolites with anticoag-
ulant activity similar to that of the parent drug (data on file).
However, because of low abundance (\10 % for each) [5],
these metabolites are not expected to contribute significantly
to total anticoagulant activity in normal circumstances.
Edoxaban is a substrate for the efflux transporter P-glyco-
protein (P-gp), and M4 is a substrate for uptake transporter
organic anion–transporting polypeptide (OATP) 1B1 [6].
Previous drug–drug interaction studies demonstrated
increased exposure to edoxaban when it was coadministered
with P-gp inhibitors such as quinidine, verapamil and dro-
nedarone (increases of 77, 53 and 85 %, respectively) [7].
Interactions involving transporters may affect drug or
metabolite exposure and safety profiles in various tissues.
Thus, the US Food and Drug Administration recommends
evaluation of the effects of transporter-based drug inter-
actions on absorption and disposition of investigational
drugs [8]. Rifampin is a potent inducer of CYP3A4/5 and
P-gp [9, 10]. Rifampin is also an inhibitor of OATP1B1
[11], which is involved in the transport of the active
metabolite M4 [6]. This drug interaction study evaluated
the effect of multiple doses of rifampin on the single-dose
pharmacokinetics of edoxaban and its active metabolites
M4 and M6. A limited assessment of the anticoagulatory
effect was included at 2, 4 and 24 h after edoxaban dosing.
2 Methods
2.1 Study Design and Objectives
This was a phase 1, open-label, two-treatment, two-period,
fixed-sequence study conducted at a single centre. The pri-
mary objective was to evaluate the effect of multiple doses
of rifampin on the single-dose pharmacokinetics of edoxa-
ban when it was coadministered with rifampin. Plasma
concentrations of edoxaban and its active metabolites M4
and M6, and the pharmacodynamic markers prothrombin
time (PT), international normalized ratio (INR) and acti-
vated partial thromboplastin time (aPTT) were measured.
This study was nonrandomized because of the potential
carryover effects of CYP and P-gp induction by rifampin.
During period 1, all subjects received a single oral
60 mg edoxaban dose on day 1. During period 2, all sub-
jects received once-daily rifampin 600 mg (2 9 300 mg
Rifadin capsules; Sanofi Aventis, Bridgewater, NJ, USA)
on days 1 through 7, along with a single oral dose of
edoxaban 60 mg administered concomitantly on day 7.
There was a 6-day washout between treatment periods. All
treatments were administered following an overnight 10-h
fast, and food intake was prohibited for an additional 2 or
4 h following administration of rifampin or edoxaban,
respectively. Edoxaban 60 mg was selected because it was
the primary therapeutic dose used in phase 3 studies [12,
13] and is well tolerated in healthy subjects [4]. A single
rifampin 600 mg dose is the highest recommended dose for
treatment of tuberculosis [14].
The study was approved by the Celerion (formerly MDS
Pharma Services) Institutional Review Board (Lincoln, NE,
USA) and conducted in compliance with the Declaration of
Helsinki and the International Conference on Harmonisa-
tion consolidated Guideline E6 for Good Clinical Practice.
All subjects provided written informed consent prior to
screening.
2.2 Subjects
Healthy males and nonpregnant/nonbreastfeeding females,
18–45 years of age with a body mass index of 18–32 kg/
m2, were enrolled. Subjects were excluded if they had
taken any prescription or over-the-counter medications
within 14 days of the first dose of study medication, or if
they had taken St. John’s wort, anticoagulants, coagulants,
antiplatelet therapy, nonsteroidal anti-inflammatory drugs
or any drug or substance known to be a strong CYP3A4/5
or P-gp inducer or inhibitor within 30 days of the first dose
of study medication. Subjects with a history or risk of
bleeding or coagulopathy were excluded.
2.3 Sample Collection
Blood samples were collected for assessment of plasma
concentrations of edoxaban, M4 and M6 on day 1 of period 1
and on day 7 of period 2 at 0 h (before edoxaban dosing) and
at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60 and 72 h after
edoxaban dosing. Blood samples were collected for assess-
ment of rifampin plasma concentrations measured at trough
on days 1 through 7 of period 2 at 0 h (before rifampin
dosing) to confirm rifampin exposure. Blood samples for
pharmacodynamic analyses (PT and aPTT) were collected
on day 1 of period 1 and on day 7 of period 2 at 0 h (before
edoxaban dosing) and at 2, 4 and 24 h after edoxaban dosing.
2.4 Bioanalytical Methods
Plasma concentrations of edoxaban and its metabolites
were analysed by Advion BioServices (Indianapolis, IN,
USA) using two validated liquid chromatography–tandem
mass spectrometry methods.
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For simultaneous measurement of edoxaban and M4,
plasma samples (200 lL) were mixed with internal stan-
dards (d6-edoxaban and d3-M4) and loaded onto 96-well
Oasis MCXTM (mixed-mode ion exchange resin) solid-
phase extraction plates (Waters Corporation, Milford, MA,
USA). Analysis of extracted samples was performed by
gradient chromatography (flow rate 0.3 mL/min) with 5
mM ammonium acetate (pH 7.0) and methanol, using an
Agilent Zorbax Eclipse XDB Phenyl (2.1 mm 9 50 mm,
5 lm) column (Agilent Technologies, Santa Clara, CA,
USA).
For M6 measurement, plasma samples (300 lL) were
mixed with internal standards (d6-M6) and pH adjustment
solution (2 % formic acid, 200 lL), centrifuged and loaded
onto 96-well Waters MCXTM (mixed-mode cation
exchange resin) solid-phase extraction blocks (Waters
Corporation). Analysis of extracted samples was performed
by gradient chromatography (flow rate 0.5 mL/min) with 5
mM ammonium acetate (pH 7.0) and methanol over a
Waters Xbridge Phenyl (2.1 mm 9 50 mm, 3.5 lm) col-
umn (Waters Corporation).
For both methods, eluted analytes and internal standards
were detected by an API4000 mass spectrometer (SCIEX,
Framingham, MA, USA) equipped with a TurboIonSpray
source (SCIEX) in positive ion mode. For M4 and edoxa-
ban, the reaction monitoring transitions were 550.4 to
366.3 (edoxaban), 556.4 to 372.3 (d6-edoxaban), 521.4 to
339.3 (M4) and 524.4 to 342.3 (d3-M4), respectively. For
M6, the reaction monitoring transitions were 534.4 to 352.1
(M6) and 540.2 to 358.1 (d6-M6), respectively. The cali-
bration curves for edoxaban (1/x2 weighting, quadratic),
M4 (1/x2 weighting, linear) and M6 (1/x weighting, linear)
ranged from 0.764 to 382 ng/mL, from 0.0792 to 7.92 ng/
mL and from 0.1 to 5 ng/mL, respectively. Samples with
plasma concentrations [382 ng/mL were diluted with
appropriate controls. In assay validations for edoxaban, the
intra- and interassay precision (coefficient of variation
[CV]) values were B11.0 and B8.8 %, respectively, for
edoxaban quality control (QC) samples prepared at 0.764,
2.29, 153 and 306 ng/mL, and the intra- and interassay
accuracy values were -6.9 to 5.8 %. For M4, the intra- and
interassay precision (CV) values were B12.3 and B11.5 %,
respectively, for QC samples prepared at 0.0792, 0.238,
3.17 and 6.34 ng/mL, and the intra- and interassay accu-
racy values were -2.0 to 18.5 %. For M6, the intra- and
interassay precision (CV) values were B9.3 and B6.7 %,
respectively, for QC samples prepared at 0.1, 0.3, 2.0 and
4.0 ng/mL, and the intra- and interassay accuracy values
were -2.3 to 16.2 %.
Biomarkers (PT and aPTT) and rifampin plasma con-
centrations were analysed by Celerion (formally MDS
Pharma Services) (Neptune, NJ, USA) using validated
methods.
2.5 Pharmacokinetic and Pharmacodynamic
Analyses
Plasma concentration data for edoxaban and its metabolites
were analysed by noncompartmental methods using
WinNonlin Professional Version 5.2 (Pharsight Corp.,
Mountain View, CA, USA). Key parameters included the
maximum plasma concentration (Cmax), time to Cmax
(tmax), area under the plasma concentration–time curve
from time zero extrapolated to infinity (AUC?) calculated
using the log-linear trapezoidal method, and apparent ter-
minal half-life (t). Apparent total body clearance (CL/F)
was calculated for edoxaban only. Pharmacokinetic
parameters were estimated using actual sampling time
points. Biomarker data for PT and aPTT were analysed
using SAS Version 9.1.3 (Cary, NC, USA).
2.6 Safety
Safety was evaluated throughout the study via physical
examinations, vital signs, monitoring of body weight and
laboratory tests (haematology, serum chemistry, urinalysis
and electrocardiograms). In addition, adverse events (AEs)
were monitored and recorded according to the Medical
Dictionary for Regulatory Activities version 12.0. The
incidence, severity (i.e. mild, moderate or severe), duration
and potential relationship to the study medication were
captured for the AEs.
2.7 Statistical Analysis
Continuous pharmacokinetic and pharmacodynamic vari-
ables were summarized by descriptive statistics. Statistical
analyses were performed in SAS. Analysis of variance
with treatment as a fixed effect and subject as a random
effect was performed on the ln-transformed Cmax and
AUC? obtained for each treatment, and 90 % confidence
intervals (CIs) were calculated for the ratios of the geo-
metric least squares means (GLSMs) between treatments.
Absence of an effect of rifampin on edoxaban pharma-
cokinetics was concluded if the 90 % CIs about the GLSM
ratios of Cmax and AUC? of edoxaban administered with
and without rifampin were contained within the equiva-
lence interval of 80–125 %. The tmax values for edoxaban
and its metabolites were analysed using a Hodges–Leh-
mann estimator of the differences, and mean values and
CIs were generated with the Moses method.
Assuming an intra-individual CV for Cmax of 24 % for
edoxaban, based on prior studies, and assuming that
rifampin had little or no effect (ratio\1.05) on edoxaban
pharmacokinetics, a sample size of 28 subjects was
required to provide at least 80 % power to determine
absence of an effect of rifampin on Cmax and AUC of
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edoxaban with a CI of 90 % around the 80–125 % no-
effect boundaries. A total of 34 subjects were enrolled to
ensure that 28 subjects would complete the study.
3 Results
Thirty-four healthy adults aged 21–44 years were enrolled,
and 32 subjects completed the study. Table 1 summarizes
the demographic and baseline characteristics of the enrol-
led subjects. One subject was withdrawn because of an AE,
and one subject withdrew consent for participation.
The mean plasma edoxaban concentrations were similar
for edoxaban alone and for edoxaban with rifampin up to
the time when mean Cmax was reached (Fig. 1a). Plasma
edoxaban concentrations declined faster when edoxaban
was coadministered with rifampin than when it was
administered alone.
Edoxaban Cmax and tmax were similar between treat-
ments (Table 2). Concomitant administration of rifampin
with edoxaban resulted in an approximate 34 % decrease in
total exposure to edoxaban (AUC?) when compared with
administration of edoxaban alone (Table 3). Rifampin
coadministration resulted in an approximate 50 % reduc-
tion in edoxaban t and an approximate 33 % increase in
CL/F.
Both M4 and M6 formed rapidly when edoxaban was
administered with or without rifampin (Fig. 1b, c). Con-
current edoxaban and rifampin administration increased
Cmax values for M4 and M6 by 5- and 4-fold, respectively
(Table 2). Coadministration of edoxaban and rifampin
produced significant 3-fold increases in metabolite expo-
sure (Table 3). The 90 % CIs for the GLSM ratios were
greater than the upper bounds of the 80–125 % intervals
for Cmax, AUC? and tmax (Table 3). The tmax values for
M4 and M6 (Tables 2, 3) were unaffected by coadminis-
tration of rifampin with edoxaban; however, the M4 t was







































































































Fig. 1 Mean plasma concentration–time curves of edoxaban (a) and
the edoxaban metabolites M4 (b) and M6 (c) with and without
rifampin. Edoxaban = a single oral dose of edoxaban 60 mg.
Edoxaban with rifampin = 7 days of rifampin 600 mg (2 9 300
mg capsules once daily) followed by a single oral dose of edoxaban
60 mg administered concomitantly on day 7. Error bars represent
standard deviations. The insets show semi-log scale plots
Table 1 Demographic and baseline characteristics (enrolled popu-
lation, N = 34)
Characteristic Value








Not Hispanic/Latino 31 (91.2)
Age, years 30.9 ± 6.4a
Body mass index, kg/m2 26.1 ± 2.7a
a Mean ± standard deviation
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decreased by approximately 35 % when edoxaban was
coadministered with rifampin, compared with administra-
tion of edoxaban alone (Table 2).
Rifampin plasma concentrations measured at trough
each day demonstrated mean (standard deviation [SD])
concentrations of 0.21 (0.48) lg/mL on day 2 and then
decreased each day as a consequence of rifampin auto-
induction. These values were fairly consistent with his-
torical values for rifampin administered as 600 mg daily for
7 days [15, 16].
The mean baseline PT and aPTT values were similar for
both treatments. The PT and aPTT values at 2 and 4 h were
minimally different with and without rifampin (Fig. 2).
Coadministration of rifampin and edoxaban resulted in
minimal changes (\10 %) from the baseline PT and aPTT
values, compared with administration of edoxaban alone.
However, these data should be interpreted with caution, as
only early anticoagulatory effects were assessed.
Thirty-three subjects (97.1 %) reported 53 AEs during
the study. All AEs were mild in intensity. The most com-
mon AE was chromaturia (in 32 subjects), a known effect
associated with rifampin treatment [14]. The majority of
AEs occurred during edoxaban and rifampin coadminis-
tration (33 subjects) and were deemed by the investigator
to be related to rifampin. Five subjects reported AEs when
edoxaban was administered alone. Two AEs were
considered related to edoxaban treatment and included
headache (reported by one subject) and gingival bleeding
(reported by one subject); both events were mild and
resolved without treatment. One subject experienced diar-
rhoea, which was judged to be related to both rifampin and
edoxaban. No serious AEs occurred during this study. One
subject discontinued participation in the study because of a
transient elevation in serum creatinine (21 % above base-
line), which was judged by the investigator to be unrelated
to the study medication.
4 Discussion
These results suggest that the effect of rifampin on edox-
aban was not only to reduce oral bioavailability and
increase excretion through potential induction of P-gp, but
also to increase its metabolism to form the metabolite M6
through CYP3A4/5. The increase in M4 is likely due to the
inhibitory effect of rifampin on OATP1B1, as well as
potential induction of CES-1 through upregulation of the
pregnane X receptor gene [16–18]. The exact effects of
rifampin on the disposition of the metabolite M4 are not
discernible from this study alone and require further studies
(e.g. single-dose versus multiple-dose rifampin coadmin-
istered with intravenous and oral edoxaban) to better
Table 2 Pharmacokinetic parameters of edoxaban and its metabolites












rifampin, N = 32
Cmax, ng/mL 243 ± 100 257 ± 61.8 23.1 ± 13.2 108 ± 33.0 8.55 ± 4.10 44.5 ± 12.3
tmax, h 1.08 (0.50–4.00) 1.00 (0.50–3.00) 1.81 (1.00–3.05) 2.00 (1.00–3.00) 1.49 (0.983–3.00) 1.00 (0.617–3.00)
AUC?, ngh/mL 1835 ± 442 1192 ± 214 161 ± 69.8 449 ± 140 91.1 ± 28.2 261 ± 57.4
t, h 13.6 ± 6.06 6.54 ± 4.24 14.3 ± 6.0 4.23 ± 3.78 14.3 ± 5.58 10.0 ± 3.81
CL/F, L/h 34.8 ± 9.22 52.0 ± 9.76 NC NC NC NC
Metabolite to parent
exposure ratio (%)
8.89 ± 3.22 38.1 ± 11.8 5.09 ± 1.44 22.2 ± 4.35
Data are presented as arithmetic mean ± standard deviation, except for tmax values, which are presented as median (range)
AUC? area under the plasma concentration–time curve from time zero extrapolated to infinity, CL/F apparent total body clearance, Cmax
maximum plasma concentration, NC not calculated, t apparent terminal half-life, tmax time to Cmax
Table 3 Geometric least
squares mean ratios for
pharmacokinetic parameters
Parameter Ratio of edoxaban alone to edoxaban with rifampin (90 % confidence interval)
Edoxaban M4 M6
Cmax 110.1 (98.8 to 122.6) 506.4 (446.5 to 574.4) 551.9 (485.6 to 627.2)
AUC? 65.72 (62.5 to 69.1) 285.5 (264.5 to 308.1) 291.1 (274.0 to 309.4)
AUC? area under the plasma concentration–time curve from time zero extrapolated to infinity, Cmax
maximum plasma concentration, tmax time to Cmax
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elucidate OATP1B1 inhibitory effects from enzyme/trans-
porter induction effects [18].
The limitations of the study were that the mechanism of the
increase in metabolite exposure could not be further eluci-
dated. The administration of edoxaban with a single dose of
rifampin may have characterized the effect of rifampin on the
inhibition of transporters such as P-gp and OATP1B1.
Administration of intravenous edoxaban with and without
rifampin may have differentiated the prehepatic versus hep-
atic effects of rifampin on parent and metabolite exposure.
Finally, urine concentrations of edoxaban were not measured.
Since renal clearance represents approximately 50 % of the
total clearance of edoxaban, the impact of rifampin on trans-
porters in renal clearance were not characterized.
These results demonstrate a drug interaction of edoxa-
ban and its metabolites with rifampin. Induction of both
P-gp and CYP3A4/5 by rifampin explains the decreased
exposure to edoxaban and the increased exposure to M6 (a
metabolite formed via CYP3A4/5). Dosing recommenda-
tions in the US prescribing information [3] suggest that
concomitant use of edoxaban with rifampin should be
avoided because of decreased edoxaban exposure.
5 Conclusion
Rifampin significantly decreased exposure to edoxaban and
increased exposure to its active metabolites.
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